open access

Vol 9, No 2 (2006)
Short communications
Published online: 2006-06-21
Submitted: 2012-01-23
Get Citation

The effects of radioisotope therapy and radiotherapy in subjects with breast cancer with bone metastases

Małgorzata Djabełek-Maciaœ et al.
Nucl. Med. Rev 2006;9(2):138-143.

open access

Vol 9, No 2 (2006)
Short communications
Published online: 2006-06-21
Submitted: 2012-01-23

Abstract


BACKGROUND: Metastatic bone disease is found in 80-90% of patients examined after death and is a serious problem in everyday practice. The aim of the study was the evaluation of the survival time of patients with bone metastases in relation to the prognostic group and applied treatment.
MATERIAL AND METHODS: The authors analyzed 84 patients treated in the Radiotherapy Division of Lower Silesian Oncology Centre during the years 1997-2004. Radioisotope treatment was conducted in the Department of Nuclear Medicine of the 4th Military Clinical Hospital in Wrocław. The average age of the patients was 53.1 years. The women differed in staging at the moment of diagnosis. The patients were divided into two groups with different clinical prognoses. In addition to systemic treatment (biphosphonates, chemotherapy or hormonotherapy), 32 (38.1%) patients were treated with teletherapy and 20 (23.8%) underwent radioisotope therapy. In 32 (38.1%) patients both methods were applied. The analysis of results included the estimation of overall survival (OS) meaning the time of survival from the onset of disease to one of the end points. End points of the observation were defined by the authors as the patient’s death or last control visit. The Kaplan-Meier method was used.
RESULTS: The outcomes of the observation are closely connected with particular prognostic groups. The Kaplan-Meier’s diagrams presented here indicate that teletherapy combined with radioisotope therapy was the most beneficial for the patients with metastases in bones and other organs.
CONCLUSIONS: The best effects of the treatment measured by overall survival were obtained with combined treatment: radiotherapy and radioisotopes, in the group with bone and extra- skeletal metastases.

Abstract


BACKGROUND: Metastatic bone disease is found in 80-90% of patients examined after death and is a serious problem in everyday practice. The aim of the study was the evaluation of the survival time of patients with bone metastases in relation to the prognostic group and applied treatment.
MATERIAL AND METHODS: The authors analyzed 84 patients treated in the Radiotherapy Division of Lower Silesian Oncology Centre during the years 1997-2004. Radioisotope treatment was conducted in the Department of Nuclear Medicine of the 4th Military Clinical Hospital in Wrocław. The average age of the patients was 53.1 years. The women differed in staging at the moment of diagnosis. The patients were divided into two groups with different clinical prognoses. In addition to systemic treatment (biphosphonates, chemotherapy or hormonotherapy), 32 (38.1%) patients were treated with teletherapy and 20 (23.8%) underwent radioisotope therapy. In 32 (38.1%) patients both methods were applied. The analysis of results included the estimation of overall survival (OS) meaning the time of survival from the onset of disease to one of the end points. End points of the observation were defined by the authors as the patient’s death or last control visit. The Kaplan-Meier method was used.
RESULTS: The outcomes of the observation are closely connected with particular prognostic groups. The Kaplan-Meier’s diagrams presented here indicate that teletherapy combined with radioisotope therapy was the most beneficial for the patients with metastases in bones and other organs.
CONCLUSIONS: The best effects of the treatment measured by overall survival were obtained with combined treatment: radiotherapy and radioisotopes, in the group with bone and extra- skeletal metastases.
Get Citation

Keywords

bone metastases; breast cancer; bone pain; radiopharmaceuticals

About this article
Title

The effects of radioisotope therapy and radiotherapy in subjects with breast cancer with bone metastases

Journal

Nuclear Medicine Review

Issue

Vol 9, No 2 (2006)

Pages

138-143

Published online

2006-06-21

Bibliographic record

Nucl. Med. Rev 2006;9(2):138-143.

Keywords

bone metastases
breast cancer
bone pain
radiopharmaceuticals

Authors

Małgorzata Djabełek-Maciaœ et al.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl